• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Established Executive and Milwaukee Business Leader Jim Emling Joins VBA as Executive Chair of the Board of Directors

    11/28/23 5:00:00 PM ET
    $DH
    $GDRX
    Computer Software: Prepackaged Software
    Technology
    EDP Services
    Technology
    Get the next $DH alert in real time by email

    Jim Emling, the CEO of Datassential and former long-time president of Milwaukee-based Zywave, has been appointed Executive Chair of the Board of Directors at VBA, the company announced today.

    "We are delighted to welcome Jim officially to VBA as the Executive Chair," said Michael Clayton, the company's President and CEO. "Jim and I have worked closely together over the last 3 months and his decades of experience scaling high growth software companies combined with his strong ties to the Milwaukee technology sector will be tremendous assets to VBA as we enter our next phase of growth."

    Emling has deep roots in the Milwaukee technology community. He was the founding CTO of Zywave and served as its president for 17 years. During his tenure, he led the company from $0 to $100 million in revenue and employed hundreds of people. The Expert Institute, where he currently serves as Board Director, opened an office in the 3rd ward and employs over 75 people in the area. Datassential also has a Milwaukee satellite office.

    Emling joins VBA at a time when the company is heavily investing in sales and product development, having recently closed a growth equity transaction led by Spectrum Equity and Arthur Ventures. Spectrum is a leading growth equity firm that has backed numerous healthcare technology businesses such as Definitive Healthcare (NASDAQ:DH), GoodRx (NASDAQ:GDRX) and Payer Compass (acquired by Zelis).

    VBA makes the health care experience better for everyone by eliminating data fragmentation and enabling interoperability through its tightly integrated suite of solutions. VBA serves the entire payer landscape, including third party administrators (TPAs) and health plans, with its next-gen Core Administrative Processing System ("CAPS"), user engagement platforms, customer support tools, population health reporting solution and robust data connections. The company's cloud-based software solutions enable payers to replace outdated legacy systems, grow their business and reduce costs.

    "It's a really exciting time to join VBA," said Emling. "The company has a reputation for delivering a unique and differentiated software product to customers across the entire healthcare payer landscape. I'm looking forward to helping the company continue to widen its product lead and scale its go-to-market activities."

    About VBA

    VBA is a leading-edge healthcare technology company providing comprehensive software solutions for healthcare payers. Uniquely delivered on a secure, cloud-based platform, VBA provides a suite of technology solutions for core benefits administration. These include a core administrative processing system (VBASoftware), user engagement platforms (VBAGateway), customer support tools (VBAVoice), population health reporting solutions (VBAnalytics) and API-driven data connections (VBAPI). Learn more at https://vbasoftware.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231128218277/en/

    Get the next $DH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DH
    $GDRX

    CompanyDatePrice TargetRatingAnalyst
    GoodRx Holdings Inc.
    $GDRX
    8/11/2025Strong Buy → Outperform
    Raymond James
    Definitive Healthcare Corp.
    $DH
    5/9/2025Buy → Neutral
    BTIG Research
    Definitive Healthcare Corp.
    $DH
    1/13/2025$4.00Equal Weight → Underweight
    Barclays
    Definitive Healthcare Corp.
    $DH
    12/20/2024$5.00Equal-Weight
    Stephens
    GoodRx Holdings Inc.
    $GDRX
    12/4/2024$5.00Neutral
    Mizuho
    Definitive Healthcare Corp.
    $DH
    9/17/2024$7.00Buy
    BTIG Research
    GoodRx Holdings Inc.
    $GDRX
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    Definitive Healthcare Corp.
    $DH
    7/31/2024$7.00 → $5.00Neutral → Underweight
    JP Morgan
    More analyst ratings

    $DH
    $GDRX
    SEC Filings

    View All

    SEC Form 10-Q filed by Definitive Healthcare Corp.

    10-Q - Definitive Healthcare Corp. (0001861795) (Filer)

    8/7/25 4:23:27 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    Definitive Healthcare Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Definitive Healthcare Corp. (0001861795) (Filer)

    8/7/25 4:13:26 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    SEC Form 10-Q filed by GoodRx Holdings Inc.

    10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)

    8/6/25 4:20:51 PM ET
    $GDRX
    EDP Services
    Technology

    $DH
    $GDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    12/4/23 4:35:10 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/30/23 4:41:35 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/17/23 7:08:30 PM ET
    $GDRX
    EDP Services
    Technology

    $DH
    $GDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GoodRx Announces Collaboration with Novo Nordisk to Expand Access to Ozempic® and Wegovy® for $499-Per-Month

    Until today, Ozempic® has not been available to eligible self-paying patients at this price GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with Novo Nordisk, all strengths of Ozempic® (semaglutide) and Wegovy® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective today. This collaboration significantly lowers the price available on GoodRx for two of the most in-demand GLP-1 medications nationwide, expanding access for those who lack adequate insurance coverage. Today also marks the first time Ozempic® has been made available to patients at this self-pay price.

    8/18/25 9:05:00 AM ET
    $GDRX
    EDP Services
    Technology

    Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2025

    FRAMINGHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended June 30, 2025.  Second Quarter 2025 Financial Highlights: Revenue was $60.8 million, a decrease of 5% from $63.7 million in Q2 2024. Net Loss was $(9.3) million, or (15)% of revenue, compared to $(306.2) million in Q2 2024, inclusive of goodwill impairment charges of $363.6 million, or (480)% of revenue.Adjusted Net Income was $9.7 million, compared to $14.2 million in Q2 2024.Adjusted EBITDA was $18.7 million, or 31% of revenue, compared to

    8/7/25 4:05:00 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    GoodRx Reports Second Quarter 2025 Results

    Second Quarter 2025 Revenue and Adjusted EBITDA Margin in Line with Previous Guidance; Pharma Manufacturer Solutions Revenue Increased 32% Year-Over-Year GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2025. Second Quarter 2025 Highlights Revenue of $203.1 million Net income of $12.8 million; Net income margin of 6.3% Adjusted Net Income1 of $33.9 million; Adjusted Net Income Margin1 of 16.7% Adjusted EBITDA1 of $69.4 million; Adjusted EBITDA Margin1 of 34.2% Net cash provided by operating activities of $49.6 million

    8/6/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    $DH
    $GDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GoodRx downgraded by Raymond James

    Raymond James downgraded GoodRx from Strong Buy to Outperform

    8/11/25 9:45:40 AM ET
    $GDRX
    EDP Services
    Technology

    Definitive Healthcare downgraded by BTIG Research

    BTIG Research downgraded Definitive Healthcare from Buy to Neutral

    5/9/25 8:41:31 AM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    Definitive Healthcare downgraded by Barclays with a new price target

    Barclays downgraded Definitive Healthcare from Equal Weight to Underweight and set a new price target of $4.00

    1/13/25 7:41:23 AM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    $DH
    $GDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rey-Giraud Agnes gifted 75,219 shares and received a gift of 75,219 shares, decreasing direct ownership by 47% to 85,448 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    8/19/25 6:07:00 PM ET
    $GDRX
    EDP Services
    Technology

    Chief Accounting Officer Nabiey Romin covered exercise/tax liability with 1,719 shares and converted options into 4,804 shares, increasing direct ownership by 2% to 137,292 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    8/15/25 6:36:46 PM ET
    $GDRX
    EDP Services
    Technology

    Chief Accounting Officer Nabiey Romin converted options into 12,663 shares and covered exercise/tax liability with 4,531 shares, increasing direct ownership by 6% to 134,207 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    8/8/25 5:15:01 PM ET
    $GDRX
    EDP Services
    Technology

    $DH
    $GDRX
    Financials

    Live finance-specific insights

    View All

    Definitive Healthcare Reports Financial Results for Second Quarter Fiscal Year 2025

    FRAMINGHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended June 30, 2025.  Second Quarter 2025 Financial Highlights: Revenue was $60.8 million, a decrease of 5% from $63.7 million in Q2 2024. Net Loss was $(9.3) million, or (15)% of revenue, compared to $(306.2) million in Q2 2024, inclusive of goodwill impairment charges of $363.6 million, or (480)% of revenue.Adjusted Net Income was $9.7 million, compared to $14.2 million in Q2 2024.Adjusted EBITDA was $18.7 million, or 31% of revenue, compared to

    8/7/25 4:05:00 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    GoodRx Reports Second Quarter 2025 Results

    Second Quarter 2025 Revenue and Adjusted EBITDA Margin in Line with Previous Guidance; Pharma Manufacturer Solutions Revenue Increased 32% Year-Over-Year GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2025. Second Quarter 2025 Highlights Revenue of $203.1 million Net income of $12.8 million; Net income margin of 6.3% Adjusted Net Income1 of $33.9 million; Adjusted Net Income Margin1 of 16.7% Adjusted EBITDA1 of $69.4 million; Adjusted EBITDA Margin1 of 34.2% Net cash provided by operating activities of $49.6 million

    8/6/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    Definitive Healthcare Announces Timing of Its Second Quarter 2025 Financial Results Conference Call and Webcast

    FRAMINGHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its second quarter ended June 30, 2025, on Thursday, August 7, 2025 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international). Shortl

    7/24/25 4:05:00 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    $DH
    $GDRX
    Leadership Updates

    Live Leadership Updates

    View All

    GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

    Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T

    7/28/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Open Sources Lifecycle to Support Innovation in Software Development Velocity and Developer Productivity

    Public release of Lifecycle reflects company's commitment to transparency, innovation, and community collaboration GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced it is open-sourcing Lifecycle, a homegrown development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. Lifecycle is now available to the public under the Apache 2.0 license, inviting developers and organizations to adopt, contribute to, and build upon the platform. The tool allows engineering, quality assurance, and platform teams to automatically spin up short-lived, isolated environments—known as ephemeral environments—for

    6/5/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

    Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

    3/17/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    $DH
    $GDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/14/24 12:29:56 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/13/24 4:30:24 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/12/24 4:02:41 PM ET
    $GDRX
    EDP Services
    Technology